涉及MLLT10融合的结构变异与儿童急性髓系白血病不良结局相关
该回顾性研究纳入儿童肿瘤学组AAML0531和AAML1031试验中2080例儿童及年轻成人急性髓系白血病患者,通过转录组分析和/或核型分析鉴定MLLT10融合。127例(6.1%)携带MLLT10融合,其5年无事件生存率18.6% vs 无MLLT10者49%,5年总生存率38.2% vs 65.7%,复发风险76% vs 38.6%。
要点
- MLLT10融合见于6.1%的儿童AML,以KMT2A::MLLT10为主(81.9%)。
- MLLT10融合患者5年EFS 18.6% vs 无融合者49%,OS 38.2% vs 65.7%,复发风险76% vs 38.6%。
- 无论融合伴侣如何,MLLT10融合AML均呈极高危特征,应优先考虑替代治疗干预。
核心结论
- 携带MLLT10融合的AML患者无论融合伴侣如何均呈现极高危特征,应优先考虑替代治疗干预。
研究设计与样本
- 回顾性研究纳入儿童肿瘤学组AAML0531(NCT00372593)和AAML1031(NCT01371981)试验注册的2080例儿童及年轻成人AML患者,进行转录组分析和/或核型分析以鉴定与预后相关的白血病融合。
主要发现
- 127例(6.1%)检出MLLT10融合:104例(81.9%)为KMT2A::MLLT10,13例(10.2%)为PICALM::MLLT10,10例(7.9%)为X::MLLT10(DDX3X和TEC各2例),另有6种伴侣(DDX3Y、CEP164、SCN2B、TREH、NAP1L1和XPO1)各见于单例患者。
- MLLT10融合患者(n=127)5年无事件生存率18.6% vs 无MLLT10者(n=1953)49%(P < .001),5年总生存率38.2% vs 65.7%(P ≤ .001),复发风险76% vs 38.6%(P < .001)。
- KMT2A::MLLT10患者自研究入组起的EFS为19.5% vs 其他MLLT10融合伴侣者12.7%(P = .628),OS为40.4% vs 27.6%(P = .361)。
- PICALM::MLLT10患者EFS为9.2% vs 无PICALM的其他MLLT10融合(X::MLLT10)20%(P = .788)。
- PICALM::MLLT10和X::MLLT10融合患者呈现类似NUP98::NSD1融合的DNA高甲基化特征,而KMT2A::MLLT10患者主要为影响远端调控元件的异常。
临床怎么用
- 作者认为,携带MLLT10融合的AML患者无论融合伴侣如何均呈极高危特征,应优先考虑替代治疗干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MLLT10 gene rearrangements with KMT2A occur in pediatric acute myeloid leukemia (AML) and confer poor prognosis, but the prognostic impact of MLLT10 in partnership with other genes is unknown. We conducted a retrospective study with 2080 children and young adults with AML registered on the Children's Oncology Group AAML0531 (NCT00372593) and AAML1031 trials (NCT01371981). Transcriptome profiling and/or karyotyping were performed to identify leukemia-associated fusions associated with prognosis. Collectively, 127 patients (6.1%) were identified with MLLT10 fusions: 104 (81.9%) with KMT2A::MLLT10, 13 (10.2%) with PICALM::MLLT10, and 10 (7.9%) X::MLLT10: (2 each of DDX3X and TEC), with 6 partners (DDX3Y, CEP164, SCN2B, TREH, NAP1L1, and XPO1) observed in single patients. Patients with MLLT10 (n = 127) demonstrated adverse outcomes, with 5-year event-free survival (EFS) of 18.6% vs 49% in patients without MLLT10 (n = 1953, P < .001), inferior 5-year overall survival (OS) of 38.2% vs 65.7% (P ≤ .001), and a higher relapse risk of 76% vs 38.6% (P < .001). Patients with KMT2A::MLLT10 had an EFS from study entry of 19.5% vs 12.7% (P = .628), and an OS from study entry of 40.4% vs 27.6% (P = .361) in those with other MLLT10 fusion partners. Patients with PICALM::MLLT10 had an EFS of 9.2% vs 20% in other MLLT10- without PICALM (X::MLLT10; P = .788). Patients with PICALM::MLLT10 and X::MLLT10 fusions exhibit a DNA hypermethylation signature resembling NUP98::NSD1 fusions, whereas patients with KMT2A::MLLT10 bear aberrations primarily affecting distal regulatory elements. Regardless of the fusion partner, patients with AML harboring MLLT10 fusions exhibit very high-risk features and should be prioritized for alternative therapeutic interventions.
引用
- Abla O, Ries RE, Triche T, et al. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Adv. 2024. PMID: 38306602. doi:10.1182/bloodadvances.2023010805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。